title: Treatment response to sildenafil in men with erectile dysfunction relative to concomitant comorbidities and age.
abstract: OBJECTIVE
  To evaluate treatment response in men with erectile dysfunction (ED) and concomitant comorbidities.
  
  
  METHODS
  Data were pooled from 42 placebo-controlled, flexible-dose sildenafil trials. In most trials, the sildenafil dose was 50 mg, taken ~1 hour before sexual activity but not more than once daily, with adjustment to 100 or 25 mg as needed. The overall population (N=9413) was stratified by age (<45, 46-64, ≥65 years). Treatment response was defined as a minimal clinically important difference (MCID) from baseline in the International Index of Erectile Function-Erectile Function (IIEF-EF) domain score of >2, >5 and >7 for men with mild, moderate and severe ED at baseline, respectively, or an IIEF-EF domain score ≥26 (no ED) at end-point.
  
  
  RESULTS
  In the overall population, treatment response using the IIEF-EF MCID definition was significantly greater (P<.0001) with sildenafil vs placebo in men with no comorbidity (77% vs 33%), cardiovascular disease/hypertension only (71% vs 27%), diabetes only (63% vs 24%) or depression only (78% vs 29%). Using an IIEF-EF score ≥26, treatment response was significantly greater (P<.0001) with sildenafil vs placebo in men with no comorbidity (49% vs 17%), cardiovascular disease/hypertension only (48% vs 12%), diabetes only (40% vs 12%) or depression only (60% vs 17%). With each definition, the treatment response for each age and comorbidity was significantly greater (P≤.0065) with sildenafil vs placebo.
  
  
  CONCLUSIONS
  The treatment response was significantly greater with sildenafil vs placebo in men with ED and each comorbidity regardless of age.
authors.affiliation: San Diego Sexual Medicine, Alvarado Hospital, San Diego, CA, USA.
authors.forename: Irwin
authors.initials: I
authors.lastname: Goldstein
authors.affiliation: Medical, Pfizer Inc, New York, NY, USA.
authors.forename: Vera
authors.initials: V
authors.lastname: Stecher
authors.affiliation: Global Product Development, Pfizer Inc, New York, NY, USA.
authors.forename: Martin
authors.initials: M
authors.lastname: Carlsson
mesh_terms: D000368:Aged; D002318:Cardiovascular Diseases / Q000453:epidemiology; D003863:Depression / Q000453:epidemiology; D003924:Diabetes Mellitus, Type 2 / Q000453:epidemiology; D007172:Erectile Dysfunction / Q000188:drug therapy* / Q000453:epidemiology*; D006304:Health Status; D006801:Humans; D006973:Hypertension / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D012074:Remission Induction; D012307:Risk Factors; D012720:Severity of Illness Index; D000068677:Sildenafil Citrate / Q000627:therapeutic use*; D014665:Vasodilator Agents / Q000627:therapeutic use*
chemical_list: D014665:Vasodilator Agents; D000068677:Sildenafil Citrate